Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons

Chrispin Chaguza, Andreas Coppi, Rebecca Earnest, David Ferguson, Nicholas Kerantzas, Frederick Warner, H. Patrick Young, Mallery I. Breban, Kendall Billig, Robert Tobias Koch, Kien Pham, Chaney C. Kalinich, Isabel M. Ott, Joseph R. Fauver, Anne M. Hahn, Irina R. Tikhonova, Christopher Castaldi, Bony De Kumar, Christian M. Pettker, Joshua L. Warren, Daniel M. Weinberger, Marie L. Landry, David R. Peaper, Wade Schulz, Chantal B.F. Vogels, Nathan D. Grubaugh
doi: https://doi.org/10.1101/2022.01.22.22269660
Chrispin Chaguza
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chrispin.chaguza@yale.edu nathan.grubaugh@yale.edu
Andreas Coppi
2Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
3Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Earnest
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ferguson
3Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Kerantzas
3Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederick Warner
3Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Patrick Young
3Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mallery I. Breban
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kendall Billig
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Tobias Koch
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kien Pham
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaney C. Kalinich
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel M. Ott
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph R. Fauver
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
4College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M. Hahn
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina R. Tikhonova
5Yale Center for Genome Analysis, Yale University, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Castaldi
5Yale Center for Genome Analysis, Yale University, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bony De Kumar
5Yale Center for Genome Analysis, Yale University, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian M. Pettker
6Quality and Safety, Yale New Haven Health, New Haven, CT, USA
7Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua L. Warren
8Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel M. Weinberger
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie L. Landry
9Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
10Section of Infectious Diseases, Department of Medicine, Yale School of Medicine, New Haven, CT, USA
11Clinical Virology Laboratory, Yale New Haven Hospital, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Peaper
9Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wade Schulz
3Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
9Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal B.F. Vogels
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan D. Grubaugh
1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
12Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chrispin.chaguza@yale.edu nathan.grubaugh@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continues to shape the coronavirus disease 2019 (Covid-19) pandemic. The detection and rapid spread of the SARS-CoV-2 ‘ Omicron’ variant (lineage B.1.1.529) in Botswana and South Africa became a global concern because it contained 15 mutations in the spike protein immunogenic receptor binding domain and was less neutralized by sera derived from vaccinees compared to the previously dominant Delta variant. To investigate if Omicron is more likely than Delta to cause infections in vaccinated persons, we analyzed 37,877 nasal swab PCR tests conducted from 12-26 December 2021 and calculated the test positivity rates for each variant by vaccination status. We found that the positivity rate among unvaccinated persons was higher for Delta (5.2%) than Omicron (4.5%). We found similar results in persons who received a single vaccine dose. Conversely, our results show that Omicron had higher positivity rates than Delta among those who received two doses within five months (Omicron = 4.7% vs. Delta = 2.6%), two doses more than five months ago (4.2% vs. 2.9%), and three vaccine doses (2.2% vs. 0.9%). Our estimates of Omicron positivity rates in persons receiving one or two vaccine doses were not significantly lower than unvaccinated persons but were 49.7% lower after three doses. In comparison, the reduction in Delta positivity rates from unvaccinated to 2 vaccine doses was 45.6-49.6% and to 3 vaccine doses was 83.2%. Despite the higher positivity rates for Omicron in vaccinated persons, we still found that 91.2% of the Omicron infections in our study occurred in persons who were eligible for 1 or more vaccine doses at the time of PCR testing. In conclusion, escape from vaccine-induced immunity likely contributed to the rapid rise in Omicron infections.

Competing Interest Statement

NDG is a paid consultant for Tempus Labs and the National Basketball Association.

Funding Statement

This work was supported by CTSA Grant Number TL1 TR001864 (R.E.), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (N.D.G.), and the Centers for Disease Control and Prevention (CDC) Broad Agency Announcement # 75D30120C09570 (N.D.G.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board from the Yale University Human Research Protection Program determined that obtaining de-identified test results linked to vaccination status and sequencing of de-identified remnant COVID-19 clinical samples obtained from clinical partners conducted in this study is not research involving human subjects (IRB Protocol ID: 2000031374).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵# Co-senior author

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 25, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons
Chrispin Chaguza, Andreas Coppi, Rebecca Earnest, David Ferguson, Nicholas Kerantzas, Frederick Warner, H. Patrick Young, Mallery I. Breban, Kendall Billig, Robert Tobias Koch, Kien Pham, Chaney C. Kalinich, Isabel M. Ott, Joseph R. Fauver, Anne M. Hahn, Irina R. Tikhonova, Christopher Castaldi, Bony De Kumar, Christian M. Pettker, Joshua L. Warren, Daniel M. Weinberger, Marie L. Landry, David R. Peaper, Wade Schulz, Chantal B.F. Vogels, Nathan D. Grubaugh
medRxiv 2022.01.22.22269660; doi: https://doi.org/10.1101/2022.01.22.22269660
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons
Chrispin Chaguza, Andreas Coppi, Rebecca Earnest, David Ferguson, Nicholas Kerantzas, Frederick Warner, H. Patrick Young, Mallery I. Breban, Kendall Billig, Robert Tobias Koch, Kien Pham, Chaney C. Kalinich, Isabel M. Ott, Joseph R. Fauver, Anne M. Hahn, Irina R. Tikhonova, Christopher Castaldi, Bony De Kumar, Christian M. Pettker, Joshua L. Warren, Daniel M. Weinberger, Marie L. Landry, David R. Peaper, Wade Schulz, Chantal B.F. Vogels, Nathan D. Grubaugh
medRxiv 2022.01.22.22269660; doi: https://doi.org/10.1101/2022.01.22.22269660

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1245)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (534)
  • Epidemiology (10032)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2464)
  • Geriatric Medicine (238)
  • Health Economics (480)
  • Health Informatics (1647)
  • Health Policy (754)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11872)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2290)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1249)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (734)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4843)
  • Radiology and Imaging (843)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (652)
  • Rheumatology (286)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (269)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)